AdvanCell
Sydney, Australia · Biotechnology, Health Care, Therapeutics · 85 employees
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing capabilities and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that impro
Funding history
- Series D — $315.0M — Jul 2026
- Series C — $112.0M — Feb 2025
- Venture - Series Unknown — $5.0M — Dec 2023
- Series B — Undisclosed — Aug 2022
Recent signals
- Jul 15, 2026: Raised $315.0M in Series D
- Jun 08, 2026: AdvanCell Appoints Justyna Kelly as Chief Technology Officer and François Gaudet as Chief Scientific Officer
- Nov 17, 2025: AdvanCell Appoints Philina Lee as Chief Executive Officer
- Feb 03, 2025: Launched AdvanCell successfully completes Series C funding of $112 million to advance its clinical radio-pharmaceuticals for cancer therapy.
- Feb 03, 2025: Raised $112.0M in Series C
- May 08, 2024: AdvanCell Appoints Chris Horvath as Chief Commercial and Operating Officer and Gary Li as Chief Strategy Officer
- Jan 04, 2024: AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer
- Dec 28, 2023: Raised $5.0M in Venture - Series Unknown
See plans & pricing → Track AdvanCell’s funding, hiring, and signals — with verified contacts — on Fundz.